DEVELOPMENT OF THERAPEUTIC AND DIAGNOSTIC TACTICS FOR NON-MUSCLE-INVASIVE BLADDER CANCER USING MINIMALLY INVASIVE TECHNOLOGIES
Keywords:
non-invasive bladder cancer, transurethral resection of the bladder, photodynamic therapy + TUR diagnostics and treatment of bladder cancerAbstract
Не мышечно инвазивный рак мочевого пузыря составляет 75% от общего числа больных РМП, однако характеризуется выраженной тенденцией к рецидированию в 50-70% , причем 10-30% из них прогрессирует в инвазивные и метастатические формы Обсуждаются проблемы, ранння диагностика и новые методы лечение неинвазивного рака мочевого пузыря первой стадии.
References
Tillyashaykhov M.N., Ibragimova Sh.N., Dzanklich S.M. The state of oncological care for the population of the Republic of Uzbekistan in 2019 // Fundamental research - 2020. - No. 1. - P. 8.
Matveev B.P., Figurin K.M., Kariakin O.B. Bladder cancer // Oncourology. - 2017. - No. 12. - P.54.
Malignant neoplasms in Russia in 2010 (incidence and mortality). Edited by V.I. Chissov, V.V. Starinsky, G.V. Petrova. Moscow, 2020.
Matveev B.P. Clinical oncourology. Moscow, 2021.5. Dominguez G., Carballido J., Silva J. et al. p14ARF promoter hypermethylation in plasma DNA as an indicator of disease recurrence in bladder cancer patients. ClinCancerRes2020;8:980-5.
Русаков И.Г., Быстров А.А. Хирургическое лечение, химио- и иммунотерапии больных поверхностным раком мочевого пузыря. Практонкол2023;1:107-16.
Herr H.W. The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol1999;162:74-6.
Klan. R., Loy V., Huland H. Residual tumor discovered in routine second TUR in patients with stage T1 transitional cell carcinoma of the bladder. J Urol 2022;146:316.
Herr H., Dalbagni G. Is second-look (re-staging) Transurethral resection of bladder tumors a new standard of care? Arab J Urol2021;9:7-10.
Ali M.H., Ismail I.Y., Eltobgy A., Gobeish A. Evaluation of second-look transurethral resection in restaging of patients with nonmuscle-invasive bladder cancer. J Endourol 2020;24(12):2047-50.
Dalbagni G., Vora K., Kaag M. et al. Clinical Outcome in a Contemporary Series of Restaged Patients with Clinical T1. Blad Cancer 2023;56:903-10.
Divrik R.T., Ali F.S., et al. Impact of Routine Second Transurethral Resection on the Long-Term Outcome of Patients with Newly Diagnosed pT1 Urothelial Carcinoma with Respect to Recurrence, Progression Rate, and Disease-Specific Survival: A Prospective randomized Clinical Trial. Eur Urol 2020;5(8):185-90.
Han K.S., Kyung Seok Han, Jae Young Joung et al. Results of repeated transurethral resection for a second opinion in patients referred for nonmuscle invasive bladder cancer. J Endourol2008;22(12):2699-704.
Schips L., Augustin H., Zigeuner R.E. et al. Is repeated transurethral resection justified in patients with newly diagnosed superficial bladder cancer? Urology 2022;59(2):220-3.
Schwaibold H.E., Sivalingam S., May F. et al. The value of a second transurethral resection for T1 bladder cancer. BJU Int 2006;97:1199-201.
Cheng L., Montironi R., Davidson D., Lopez-Beltran A. Staging and reporting of urothelialcarcinomaof the urinary bladder. Mod Pathol2023;22:70-95.
Zlotta A.R., van Vooren J.P., Huygen K. et al. What is the optimal regimen for BCG intravesical therapy? Are six weekly instillations necessary? Eur Urol 2023;37(4):470-7. 18. Herr H.W. restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy. J Urol2020;174:2134-7.
Stern M. Resections of obstructions at the vesical orifice. J Am Med Asso 2019;87:1726-9.
Herr H.W., Donat S.M., Dalbagni G. Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy? Department of Urology, Memorial Sloan-Kettering Cancer Center. New York. NY, 2017.
Grimm M.O., Steinhoff Ch., Simon X. et al. Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. J Urol 2023;170(2 Pt 1):433-7.
Kulkarni G.S., Oliver W. Hakenberg, Juergen E. Gschwend et al. An Updated Critical Analysis of the Treatment Strategy for Newly Diagnosed High-grade T1 (Previosly T1G3) Bladder Cancer Accepted 26 August 2020. Eur Urol 2020;57(1):60-70.
Tuychiev A.P. et al. Survival Prognosis Factors in Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder After Radical Cystectomy // Central Asian journal of medical and natural sciences . – 2021. – T. 2. – No. 5. – S. 254-261 .
Tillyashaikhov M.N., Khasanov Sh.T., Rakhimov N.M. Modified method of urine diversion after radical cystectomy for invasive bladder cancer //Medical news. – 2019. – No. 8 (299). – pp. 27-
Статья поступила в редакцию 15.07.2024; одобрена после рецензирования 20.08.2024; принята к публикации 24.08.2024.
The article was submitted 15.07.2024; approved after reviewing 20.08.2024; accepted for publication 24.08.2024.
Информация об авторах:
Юсупбеков Аброрбек Ахмеджанович- д.м.н., профессор, зам. Директора по науке РСНПЦОиР. , Республиканский Специализированный Научно Практический Медицинский Центр Онкологии и Радиологии, Узбекистан. Е-mail: res onco@mail.ru
Тилляшайхова Рано Мирзаголибовна- PhD, докторант РСНПЦОиР. Республиканский Специализированный Научно Практический Медицинский Центр Онкологии и Радиологии, Самарканд, Узбекистан. Е-mail: rano9519683@mail.ru
Туйчиев Анвар Пардабаевич PhD, аспирант РСНПЦОиР. Республиканский Специализированный Научно Практический Медицинский Центр Онкологии и Радиологии, Самарканд, Узбекистан. Е-mail: urolog-1@mail.ru
Источники финансирования: Работа не имела специального финансирования.
Конфликт интересов: Авторы декларируют отсутствие явных и потенциальных конфликтов интересов, связанных с публикацией настоящей статьи.
Вклад авторов:
Юсупбеков А.А. — идеологическая концепция работы, написание текста; редактирование статьи;
Тилляшайхова Р.М., Туйчиев А.П. — сбор и анализ источников литературы, написание текста.
Information about the authors:
Information about the authors:
Yusupbekov Abrorbek Akhmedzhanovich - Doctor of Medical Sciences, Professor, Deputy. Director of Science at RSNPCOiR. , Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology, Uzbekistan. Email: res onco@mail.ru
Tillyashaikhova Rano Mirzagolibovna is a candidate of medical Sciences, a doctoral student at the Russian National Research University. Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology, Samarkand, Uzbekistan. E-mail: rano9519683@mail.ru
Tuichiev Anvar Pardabaevich, Candidate of Medical Sciences, PhD student at the Russian National Research University. Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology, Samarkand, Uzbekistan. E-mail: urolog-1@mail.ru
Sources of funding: The work did not receive any specific funding.
Conflict of interest: The authors declare no explicit or potential conflicts of interest associated with the publication of this article.
Contribution of the authors:
Yusupbekov A.A. — the ideological concept of the work, writing the text; editing the article;
Tillyashaikhova R.M., Tuichiev A.P. — collection and analysis of literary sources, writing a text.
